Search

Intake unconfirmed. Checked 2026-10-03. Manufacture and matching of therapeutic phages, including Enterobacter cocktail Entelli02 for compassionate-use supply. Melbourne; Australia supplier AU Official Monash pages describe therapeutic phag

Case-by-case; Official referral/inquiry route. Checked 2026-10-03. Personalized therapy for difficult infections after established approaches are optimized; adults and children; multisite treatment network. Westmead; Australia network AU Of

Official referral/inquiry route. Checked 2026-10-03. Resistant infections, particularly respiratory/CF research; phage bank/matching and manufacture supporting clinical partners. Perth; Australia network AU Official compassionate-use workfl

Official referral/inquiry route. Checked 2026-10-03. Assessment for adjunctive phages in challenging bacterial infections; case selection and optimized conventional management precede treatment. Melbourne; Australia treating-center AU Offic

Official referral/inquiry route. Checked 2026-10-03. Personalized phage therapy for difficult-to-treat bacterial infections, including clinical trials and compassionate-use cases. In October 2022, STAMP administered its first patient dose o

Case-by-case; Intake unconfirmed. Checked 2026-10-03. Phage discovery, characterization and personalized preparation supporting treating clinicians; also non-clinical applications. Houston, Texas; United States supplier US Institutional ser

Historical/inactive. Checked 2026-10-03. Past childhood E. coli diarrhea randomized clinical research; report states safe administration without demonstrated clinical benefit. Dhaka; Bangladesh research-only BD Institutional annual report d

Historical/inactive. Checked 2026-10-03. BiomX's July 2026 SEC prospectus reports legacy phage operations substantially discontinued and a defense/security strategy pivot. BX004 phase 2b was discontinued December 8, 2025; former Israeli ope

Intake unconfirmed. Checked 2026-10-03. Individual-patient PJI phage research at Calgary hospitals; registry includes MSSA, Morganella and Staphylococcus lugdunensis cases. Calgary, Alberta; Canada treating-center CA Official university res

Intake unconfirmed. Checked 2026-10-04. Multidisciplinary respiratory and critical-care service describes experience with phages for multidrug-resistant lung infections. Anhui; China treating-center CN The hospital respiratory department de

Intake unconfirmed. Checked 2026-10-03. Phage bank, matching, formulation and partner-hospital investigator-initiated studies; pipeline describes nebulized A. baumannii pneumonia and K. pneumoniae urinary-infection applications. Shanghai; C

Intake unconfirmed. Checked 2026-10-03. Pediatric difficult-to-treat infections. Hospital newsletter documents nebulized personalized phages for carbapenem-resistant A. baumannii in January 2025 and describes a pediatric clinical research t

Intake unconfirmed. Checked 2026-10-03. Site in planned severe MDR Gram-negative pneumonia trial combining phages and traditional Chinese medicine. Guangzhou; China treating-center CN Listed planned site in NCT07612605; Not yet recruiting.

Intake unconfirmed. Checked 2026-10-03. Site in planned combined phage/TCM trial for severe MDR Gram-negative pneumonia. Guangzhou; China treating-center CN Listed planned site in NCT07612605; Not yet recruiting. No independent current phag

Research/development. Checked 2026-10-03. Development of MDR infection phage technology and clinical strain resources. Haikou; China research-only CN Current infectious-diseases department page describes forward planning for MDR phage treat

Status unconfirmed. Checked 2026-10-03. Personalized phage clinical research for difficult infections; historical program evidence only. Shanghai; China treating-center CN Official hospital/company material describes a phage-research partne

Intake unconfirmed. Checked 2026-10-03. MDR phage screening/engineering, clinical phage resource bank and nebulized formulations for resistant lung infection. China research-only CN Provincial Health Commission reports a human phage treatme

Intake unconfirmed. Checked 2026-10-03. Pilot six-person matched-phage study for drug-resistant infections, adults 18–75, non-IV routes; English objectives emphasize urinary infection while Chinese wording is broader. Nanjing; China treatin

Intake unconfirmed. Checked 2026-10-03. MDR A. baumannii pulmonary infections; Shanghai partners matched/manufactured phages. Regional phage/bacterial-bank research continues. Yinchuan; China treating-center CN University article reports tw

Intake unconfirmed. Checked 2026-10-03. Multicenter severe multidrug-resistant Gram-negative pneumonia study combining phages with Yiqi Huoxue Jiedu traditional Chinese medicine formula. Beijing; China treating-center CN NCT07612605 is Not